| 1 |
32720318 | Impact of the addition of carboplatin to anthracycline-taxane-based neoadjuvant chemotherapy on survival in BRCA1/2-mutated triple-negative breast cancer. | 2021 Feb 15 |
4 |
| 2 |
32497289 | Clinical outcome and toxicity from taxanes in breast cancer patients with BRCA1 and BRCA2 pathogenic germline mutations. | 2020 Aug |
2 |
| 3 |
33505905 | Insights Into the Impacts of BRCA Mutations on Clinicopathology and Management of Early-Onset Triple-Negative Breast Cancer. | 2020 |
2 |
| 4 |
28929593 | Efficacy of anthracycline/taxane-based neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1/BRCA2 mutation carriers. | 2018 May |
1 |
| 5 |
29791287 | BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study. | 2018 Aug 1 |
2 |
| 6 |
29867226 | BRCA1/2 testing: therapeutic implications for breast cancer management. | 2018 Jul |
1 |
| 7 |
25480878 | Prevalence of BRCA1 mutations and responses to neoadjuvant chemotherapy among BRCA1 carriers and non-carriers with triple-negative breast cancer. | 2015 Mar |
4 |
| 8 |
24809779 | Differential effect of MMSET mRNA levels on survival to first-line FOLFOX and second-line docetaxel in gastric cancer. | 2014 May 27 |
1 |
| 9 |
24825122 | BRCA1 promoter methylation is a marker of better response to platinum-taxane-based therapy in sporadic epithelial ovarian cancer. | 2014 Sep |
3 |
| 10 |
25414026 | Breast cancer sensitivity to neoadjuvant therapy in BRCA1 and CHEK2 mutation carriers and non-carriers. | 2014 Dec |
1 |
| 11 |
23462720 | BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study. | 2013 Apr 2 |
1 |
| 12 |
21756279 | Germline BRCA mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer. | 2012 Mar |
4 |
| 13 |
21761396 | The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. | 2012 Feb 15 |
4 |
| 14 |
22791366 | Systemic therapy options in BRCA mutation-associated breast cancer. | 2012 Sep |
1 |
| 15 |
21819606 | Drug therapy for hereditary cancers. | 2011 Aug 6 |
1 |
| 16 |
21920589 | BRCA1 is both a prognostic and predictive biomarker of response to chemotherapy in sporadic epithelial ovarian cancer. | 2011 Dec |
1 |
| 17 |
20331623 | BRCA1 and XRCC1 polymorphisms associated with survival in advanced gastric cancer treated with taxane and cisplatin. | 2010 May |
1 |
| 18 |
20471486 | Biomarkers in lung oncology. | 2010 Dec |
1 |
| 19 |
19168207 | BRCA1 and implications for response to chemotherapy in ovarian cancer. | 2009 Apr |
1 |
| 20 |
19519295 | Can the status of the breast and ovarian cancer susceptibility gene 1 product (BRCA1) predict response to taxane-based cancer therapy? | 2009 Jun |
1 |
| 21 |
18591931 | Primary resistance to docetaxel-based chemotherapy in metastatic breast cancer patients correlates with a high frequency of BRCA1 mutations. | 2008 Jul |
1 |
| 22 |
18094425 | BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. | 2007 Dec 15 |
1 |
| 23 |
16739340 | Loss of BRCA1 expression may predict shorter time-to-progression in metastatic breast cancer patients treated with taxanes. | 2006 Jan-Feb |
1 |